Tomorrow's Cell
Therapies, Today®
Pluristyx provides induced pluripotent stem cells and the expertise to accelerate the development and commercialization of revolutionary cellular therapies.
We Simplify the Stem Cell Therapy
Development Process
We Simplify the Stem Cell Therapy
Development Process
Why Pluristyx?
Pluristyx's innovative technologies, provides clients with the necessary expertise and tools to support and accelerate the development and commercialization of cellular products.
Our iPSC platform offers our clients a single point of access to our research and clinical grade stem cells, proprietary gene edits and end-to-end support throughout the product development pathway.
End-to-End Solutions
With our enlarged portfolio of unique non-modified and genetically engineered iPSC-based products, Pluristyx can assist you at any stage in your product development workflow.
Gene Edits
Offering an array of gene editing technologies and our proprietary FailSafe® edit resulting in unparalleled functional control of commercial products.
Clinical Path iPSC
Leading provider of gene-edited iPSC and cell therapy solutions, accelerating the path to clinic and providing the best route to commercialization.
Scientific Expertise
Veteran expertise from industry leaders in the field of stem cell biology, developmental genetics and cell therapy.
End-to-End Solutions
With our enlarged portfolio of unique non-modified and genetically engineered iPSC-based products, Pluristyx can assist you at any stage in your product development workflow.
Gene Edits
Offering an array of gene editing technologies and our proprietary FailSafe® edit resulting in unparalleled functional control of commercial products.
Clinical Path iPSC
Leading provider of gene-edited iPSC and cell therapy solutions, accelerating the path to clinic and providing the best route to commercialization.
Scientific Expertise
Veteran expertise from industry leaders in the field of stem cell biology, developmental genetics and cell therapy.
Try Before You Buy
Would you like to experience our technology firsthand before committing to a license agreement? We welcome you to have access to our various product offerings before you purchase a commercial license.
Your Problems, Our Solution
To overcome any obstacle you’re facing, Pluristyx offers a novel iPSC platform for rapid, efficacious, and high-quality iPS cell therapy development, can turn your bold ideas into reality.
Your Problems,
Our Solution
To overcome any obstacle you’re facing, Pluristyx offers a novel platform for rapid, efficacious, and high-quality iPSC therapy development, can turn your bold ideas into reality.
About Pluristyx
Pluristyx offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.
About Pluristyx
Pluristyx offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.
About Pluristyx
Pluristyx offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.
Latest News
Pluristyx and Solesis Announce Strategic Collaboration to Advance Organoid and Cell Therapy Solutions
SEATTLE, WA & TELFORD, PA – September 24, 2025 – Pluristyx, Inc. and Solesis, LLC today announced the signing of a Memorandum of Understanding (MOU) establishing their strategic collaboration. The primary objective is to optimize a combination of technologies to...
Pluristyx and BioLamina Announce Strategic Partnership to Accelerate Development of Stem Cell-Based Therapies
SEATTLE, WA and SUNDBYBERG, Sweden – September 4, 2025 – Pluristyx Inc., the leading provider of tools, technologies, and services for the development of induced pluripotent stem cell (iPSC) therapies, and BioLamina AB, the global leader in the development and...
Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations
Seattle, Washington: July 28, 2025 – Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, today announced the successful close of its most recent round of funding led by BioLife Solutions, the global...